ASCO 2023 | Overcoming immune checkpoint inhibitor resistance in kidney cancer

In many solid tumor cancers, there are a high number of mutations which are beneficial for immune therapy. Furthermore, large numbers of infiltrating T-cells are considered beneficial. David A. Braun, MD, PhD, Yale School of Medicine, New Haven, CT, explains how neither of these observations have been seen in kidney cancer to the same degree. In order to understand resistance, renal cell cancer (RCC) specific immune biology needs to be studied, through tumor intrinsic and tumor microenvironment studies. Factors that influence anti-tumor immunity may include T-cell exhaustion or immunosuppressive myeloid elements. In order to overcome immune checkpoint inhibitor resistance, all these areas must be targeted. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.